Phaxiam
PHAXIAM Therapeutics is a biopharmaceutical company specializing in innovative bacteriophage-based therapies to combat resistant bacterial infections. Formed from the merger of ERYTECH and PHERECYDES in June 2023, the company aims to become a global leader in phage therapy, targeting critical infections such as those caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is listed on Euronext Paris and the Nasdaq, and is involved in clinical development, strategic collaborations, and advancing treatments for severe resistance infections.
Industries
Nr. of Employees
medium (51-250)
Products
In vitro phagogram diagnostic assay
An in vitro diagnostic assay for assessing bacteriophage susceptibility of bacterial clinical isolates to guide individualized phage therapy selection.
Portfolio of clinical-grade phage candidates
A pipeline of bacteriophage therapeutic candidates targeting major hospital-acquired pathogens including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
In vitro phagogram diagnostic assay
An in vitro diagnostic assay for assessing bacteriophage susceptibility of bacterial clinical isolates to guide individualized phage therapy selection.
Portfolio of clinical-grade phage candidates
A pipeline of bacteriophage therapeutic candidates targeting major hospital-acquired pathogens including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Services
Compassionate-access treatment program
Provision of bacteriophage-based treatments to eligible patients under compassionate or early-access regulatory frameworks and collection of outcome data.
Clinical trial collaboration and support
Design and operational support for multicenter clinical trials and investigator-sponsored studies, including supply of clinical-grade phage material and scientific collaboration.
Strategic collaboration for individualized GMP therapies
Partnerships to develop and deliver individualized GMP-manufactured bacteriophage therapies and to accelerate clinical and manufacturing capabilities.
Investor relations and document distribution
Preparation and digital distribution of investor materials including financial reports, investor presentations, regulatory registration documents, press releases and subscription alerts for stakeholders.
Compassionate-access treatment program
Provision of bacteriophage-based treatments to eligible patients under compassionate or early-access regulatory frameworks and collection of outcome data.
Clinical trial collaboration and support
Design and operational support for multicenter clinical trials and investigator-sponsored studies, including supply of clinical-grade phage material and scientific collaboration.
Strategic collaboration for individualized GMP therapies
Partnerships to develop and deliver individualized GMP-manufactured bacteriophage therapies and to accelerate clinical and manufacturing capabilities.
Investor relations and document distribution
Preparation and digital distribution of investor materials including financial reports, investor presentations, regulatory registration documents, press releases and subscription alerts for stakeholders.
Expertise Areas
- Phage therapy development
- Clinical trial management (Phase I/II)
- GMP biologics manufacturing
- Regulatory affairs (IND/CTA interactions with agencies)
Key Technologies
- Bacteriophage therapeutics
- GMP bioproduction
- In vitro diagnostic assays (phagogram)
- Phage susceptibility testing